Druggist

OCTOBER 21, 2020

Amorolfine 5% nail lacquer (brand name: Curanail 5% w/v Medicated Nail Lacquer) is available as general-sale medication, which can be purchased in most supermarkets and pharmacies. The main products used for toenail fungus treatment are available in most pharmacies, supermarkets and perhaps with the best range of products found online.

Production 98

Production Containment In-Vitro Sales 98

Camargo

MARCH 25, 2021

Per the FDA’s guidance on RPDD : In vitro data supporting the mechanism of action of the drug in the disease or in a related disease may suffice for rare pediatric disease designation, whereas that level of data would not generally suffice for orphan-drug designation. Criteria for Rare Pediatric Disease Designation.

Production 130

Production Drugs In-Vitro Containment 130

Druggist

FEBRUARY 17, 2021

For many customers, ointment or cream for insect bites is the first line of rescue in stings management. In this post, I will review the best ointment or cream for insect bites available over the counter and from pharmacies. I will also discuss alternative options for insect bites, mainly the use of antihistamines. 822 Reviews. £3.19.

Pharmacy 98

Pharmacy Containment Production Sales 98

Camargo

FEBRUARY 16, 2021

The Orphan Drug Act defines a rare disease or condition as one (a) which affects less than 200,000 persons in the US or (b) for which there is no reasonable expectation that the cost of developing a drug and making it available in the US will be recovered from sales in the US. Criteria for Orphan Drug Designation. Scientific Rationale.

Production 130

Production Drugs Marketing In-Vitro 130

The Pharma Data

JANUARY 27, 2021

The collaboration with Bruker announced today will assess the suitability of the test as a professional-use in-vitro diagnostic (IVD) product for SARS-CoV-2 infection to run on Bruker’s MALDI-TOF instruments for sale in the UK and Europe. I look forward to updating the market when we have definitive clinical performance data.”.

Reagent 52

Reagent In-Vitro FDA Approval Development 52

XTalks

JUNE 12, 2023

As technology continues to revolutionize every sector of our lives, the medical device industry stands at the forefront of this innovation, playing a pivotal role in enhancing patient care, improving diagnostic accuracy and transforming treatment modalities. Note: When it comes to companies that report in foreign currencies, the conversion to U.S.

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

The Pharma Data

DECEMBER 14, 2020

The company will also pay HBM and Utrecht University a one-time license fee, payments upon achievement of certain development, regulatory, and sales-based milestones, and tiered royalties on commercial net sales. The product is designed for the prevention and treatment of COVID-19, along with related coronaviruses.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

The Pharma Data

DECEMBER 22, 2020

In vitro studies have provided compelling evidence supporting the view that Tmod-based cell therapy can distinguish tumor cells from normal cells, across multiple tumor targets,” said Dr. Under the agreement A2 will receive an upfront payment, and will be eligible for opt-in and milestone payments, plus royalties on sales of any approved product.

Development 52

Development Engineer Manufacturing In-Vitro 52

The Pharma Data

JANUARY 4, 2021

Within the collaboration, ViGeneron will optimize and validate in vitro therapeutic candidates for an undisclosed target to treat inherited eye disease. Biogen has the right to add an additional reserved target within two years after the effective date. The companies will work together on the in vivo proof of concept (POC). About ViGeneron.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

The Pharma Data

NOVEMBER 5, 2021

Roche confirms the outlook for the full year and expects a mid-single-digit sales growth at constant exchange rates. Core EPS growth at constant exchange rates is targeted to be broadly in line with sales growth. Roche intends to cancel the shares repurchased from Novartis after completion of the repurchase.

In-Vitro 52

In-Vitro Sales Genome Genomics 52

The Pharma Data

JANUARY 19, 2021

Ortho Clinical Diagnostics is a leader in in vitro diagnostics. On January 12, its VITROS SARS-CoV-2 Antigen Test for mass-scale COVID-19 testing received FDA Emergency Use Authorization. The year is starting off with a number of biopharma and life sciences initial public offerings (IPOs). TCR2 Therapeutics – The Cambridge, Mass.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

The Pharma Data

NOVEMBER 14, 2021

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in Operational Eco-Efficiency, Environmental and Social Reporting. This is based on an in-depth analysis of economic, social and environmental performance.

In-Vitro 52

In-Vitro Medicine Genome Genomics 52

The Pharma Data

AUGUST 31, 2020

About the cobas HIV-1/HIV-2 Qualitative Test cobas HIV-1/HIV-2 Qualitative for use on the cobas 6800/8800 Systems is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) RNA in human serum and plasma. .

FDA Approval 52

FDA Approval In-Vitro Antibody Medicine 52

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million principal amount of notes. The notes will mature on December 1, 2025, unless earlier repurchased, redeemed or converted.

Sales 40

Sales In-Vitro Containment Development 40

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses circulating cell-free DNA from a patient’s blood sample and uses massively parallel sequencing to detect the four main classes of genomic alterations. The test is FDA-approved to report short variants in 311 genes including rearrangements and copy number losses in BRCA1 and BRCA2 genes.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

The Pharma Data

OCTOBER 27, 2020

The test is planned for commercial launch as a CE-IVD ( in vitro diagnostic) certified product in the European Union in Q1 2021. . VANCOUVER, BC / ACCESSWIRE / October 28, 2020 / XPhyto Therapeutics Corp. “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA. SOURCE: XPhyto Therapeutics Corp. .

RNA 52

RNA Drug Delivery Production In-Vitro 52

The Pharma Data

DECEMBER 2, 2020

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec.

In-Vitro 40

In-Vitro Sales Containment Development 40

The Pharma Data

MAY 3, 2021

Other articles examined communication – one on persuasive skills, another on disseminating of regulatory intelligence – and the regulatory response to nitrosamine contamination of drug products. . . Continuous professional development. DiMichele provides valuable information on some of the available programs. . .

Development 52

Development Contamination In-Vitro Production 52

The Pharma Data

AUGUST 18, 2020

If it proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will distribute and record sales for REGN-COV2 in the U.S. REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. and around the world. Schleifer, M.D.,

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

OCTOBER 22, 2020

Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Clinical Development 40

The Pharma Data

JANUARY 13, 2021

Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19. Brilacidin is a first-in-class Host Defense Protein (HDP) mimetic with antiviral, anti-inflammatory and antibacterial properties.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

AUGUST 6, 2020

Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified. Roche’s Chief Medical Officer and Head of Global Product Development. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

DECEMBER 14, 2020

Using in-silico tools, and also generating further in-vitro data from both neuronal cell-plates, and neurospheres, LP-184 demonstrated permeability that was in line with TMZ and other therapies being used in GBM today, while also demonstrating nano-molar potency. Lantern’s A.I. ” About Lantern Pharma.

Drugs 52

Drugs Genome Genomics DNA 52

The Pharma Data

AUGUST 9, 2020

Etrolizumab met its primary endpoint of inducing remission versus placebo for people with ulcerative colitis in only two of three studies. Etrolizumab failed to meet its primary endpoint versus placebo as maintenance therapy in people with ulcerative colitis. Analyses of these data are ongoing to better understand the results.

Medicine 52

Medicine In-Vitro Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 10, 2020

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study. 97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world data.

In-Vitro 52

In-Vitro Medicine FDA Approval Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Phase III clinical trial programme initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Roche’s Chief Medical Officer and Head of Global Product Development. “We

Clinical Trials 52

Clinical Trials Clinical Trials Trials Medicine 52

The Pharma Data

SEPTEMBER 19, 2020

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy. Roche’s Chief Medical Officer and Head of Global Product Development. from 41.1% (95% CI: 33.6–48.9)

HR 52

HR Medicine In-Vitro Development 52

The Pharma Data

SEPTEMBER 2, 2020

Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations. Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Medicine 52

XTalks

JUNE 26, 2023

Medical device and in vitro diagnostics technologies provider SurModic Inc. Surmodics will manufacture and supply the device and realize revenue from product sales to Abbott as well as a share of profits from Abbott’s third-party sales. The balloon is designed for the treatment of patients with peripheral artery disease.

FDA Approval 96

FDA Approval Drugs Sales In-Vitro 96

XTalks

DECEMBER 11, 2023

Medical device companies continue to maintain a crucial role in enhancing patient care and diagnostic precision in 2023. Let’s examine the list of the top ten fastest growing medical device companies in 2023, ranked by their compound annual growth rate (CAGR). In 2021, Axonics achieved an impressive revenue of $180.3

Production 110

Production Sales In-Vitro Development 110

XTalks

SEPTEMBER 7, 2021

On the other hand, in vitro studies show that the co-administration of bamlanivimab and etesevimab retains activity against the Delta variant, but not against Delta plus and some of the earlier variants. However, new data shows that while those variants may be resistant to the drugs, the currently dominating Delta variant may not be.

Antibody 97

Antibody In-Vitro Drugs Sales 97

XTalks

DECEMBER 12, 2024

The test builds upon the MeMed BV test, which received FDA clearance in July 2023 and a CE marking under the European In Vitro Diagnostic Devices Regulation (IVDR) in the European Union (EU). The test is currently not approved for sale by any regulatory body.

In-Vitro 92

In-Vitro Immune Response Protein Sales 92

XTalks

JUNE 30, 2023

Sartorius is a globally recognized player in the diagnostics industry, providing a variety of solutions for in vitro diagnostics kit (IVD) manufacturers. In this Xtalks Spotlight feature, Xtalks spoke with two diagnostics experts from Sartoris: Wiktoria Banczyk, Strategy Analyst LPS, and Marvin (Ming) Xu, Manager of OEM DM Sales Asia.

In-Vitro 52

In-Vitro Manufacturing Production Antibody 52

XTalks

NOVEMBER 15, 2023

Valneva recently reported that it has been experiencing an increase in sales of its other vaccines due to the “recovery of the travel industry.” It appears the company has already done so as its quarterly earnings report included $96 million and $117 million of additional revenue from the sale of the PRV in its 2023 revenue guidance.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

pharmaphorum

DECEMBER 15, 2022

Woxström, a 26-year veteran of AstraZeneca, will lead sales, marketing, and commercial operations for 30 European countries plus Canada. Prior to 2022, she did sales and marketing at Pfizer, Allergan, DuPont Pharma, and Johnson & Johnson. The month of November saw a number of notable hires and personnel moves in biotech and pharma.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

pharmaphorum

AUGUST 4, 2022

If not internally, such specialist training programmes can be outsourced to third-party organisations, whether that involves pharmaceuticals, in vitro diagnostics (IVDs) or QP training. This has resulted in staff and talent shortages, meaning that industries have been forced to respond quickly to stay afloat. Harness technology.

Development 98

Development In-Vitro Manufacturing Compliance 98